Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF (Filgrastim) for Menopausal Hot Flashes
NCT03640754Phase 1Completed
- Sponsor
- MenoGeniX
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in vasomotor symptoms of menopause (VMS) and hot flashes comparing G-CSF with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events up to 16 weeks, Change From Baseline in White Blood Cell Counts at Day 84 and 3 more. Started Aug 2018; status: completed.
02
Drugs
filgrastim
03
Conditions
vasomotor symptoms of menopause (VMS)hot flashes
Beyond the preview
Go deeper on NCT03640754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640754.